Coexpression of VEGFR-3 with Sca-1, CD38, and CD41 in the murine BM
| Population . | Subpopulation . | Subpopulation as a percentage of the population ± SEM . |
|---|---|---|
| Sca-1+ | VEGFR-3+ CD41+ | 0.0 ± 0.0 |
| Sca-1+ | VEGFR-3+ CD41− | 1.8 ± 0.5 |
| Sca-1− | VEGFR-3+ CD41+ | 0.5 ± 0.3 |
| Sca-1− | VEGFR-3+ CD41− | 0.4 ± 0.2 |
| CD41+ | VEGFR-3+ | 3.0 ± 0.5 |
| CD41− | VEGFR-3+ | 2.5 ± 1.4 |
| CD38+ | VEGFR-3+ | 5.1 ± 3.8 |
| CD38− | VEGFR-3+ | 0.3 ± 0.3 |
| Population . | Subpopulation . | Subpopulation as a percentage of the population ± SEM . |
|---|---|---|
| Sca-1+ | VEGFR-3+ CD41+ | 0.0 ± 0.0 |
| Sca-1+ | VEGFR-3+ CD41− | 1.8 ± 0.5 |
| Sca-1− | VEGFR-3+ CD41+ | 0.5 ± 0.3 |
| Sca-1− | VEGFR-3+ CD41− | 0.4 ± 0.2 |
| CD41+ | VEGFR-3+ | 3.0 ± 0.5 |
| CD41− | VEGFR-3+ | 2.5 ± 1.4 |
| CD38+ | VEGFR-3+ | 5.1 ± 3.8 |
| CD38− | VEGFR-3+ | 0.3 ± 0.3 |
BM cells were isolated and populations positive and negative for Sca-1, CD41, or CD38, respectively, were enriched via MACS (column 1). The enriched CD41+, CD41−, CD38+, and CD38− populations were then further stained with VEGFR-3–specific Abs, whereas the enriched Sca-1+ and Sca-1− populations were further stained with CD41 and VEGFR-3–specific Abs (column 2). Flow cytometry was used to evaluate the percentage of the subpopulations indicated in column 2 as a fraction of the populations indicated in column 1 (n = 3). For representative plots and a more detailed description of the experimental procedure, please see supplemental Figure 3.